Extended follow-up of randomized participants in the INSIGHT START trial
Description: NARRATIVE The Strategic Timing of Antiretroviral Treatment (START) is an international randomized trial designed to determine whether initiation of ART at CD4+ counts > 500 cells/mm3 (immediate or early ART) is superior in terms of morbidity and mortality to deferral of ART until the CD4+ declines to 350 cells/mm3 (deferred ART). With this proposal, investigators in the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) will continue follow-up of the 4,684 HIV-positive participants enrolled in START through December 2021 and carry out final data analyses in 2022 and 2023.
Funding type: cooperative_agreement
Funder scheme: U01
Start date: 2019-01-01
End date: 2025-04-30
Investigator: BIRGIT GRUND
Institution: UNIVERSITY OF MINNESOTA
Funded outputs count: 48
Funder award ID: U01AI136780
OpenAlex ID: G8286752926